240 related articles for article (PubMed ID: 11053025)
1. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.
Underwood DC; Osborn RR; Bochnowicz S; Webb EF; Rieman DJ; Lee JC; Romanic AM; Adams JL; Hay DW; Griswold DE
Am J Physiol Lung Cell Mol Physiol; 2000 Nov; 279(5):L895-902. PubMed ID: 11053025
[TBL] [Abstract][Full Text] [Related]
2. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
[TBL] [Abstract][Full Text] [Related]
3. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
[TBL] [Abstract][Full Text] [Related]
4. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase.
Nick JA; Young SK; Arndt PG; Lieber JG; Suratt BT; Poch KR; Avdi NJ; Malcolm KC; Taube C; Henson PM; Worthen GS
J Immunol; 2002 Nov; 169(9):5260-9. PubMed ID: 12391245
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
[TBL] [Abstract][Full Text] [Related]
6. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
[TBL] [Abstract][Full Text] [Related]
7. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9.
Zhao L; Mu B; Zhou R; Cheng Y; Huang C
Int J Rheum Dis; 2019 Apr; 22(4):686-694. PubMed ID: 30666825
[TBL] [Abstract][Full Text] [Related]
8. Soluble epoxide hydrolase inhibitor AUDA decreases bleomycin-induced pulmonary toxicity in mice by inhibiting the p38/Smad3 pathways.
Dong XW; Jia YL; Ge LT; Jiang B; Jiang JX; Shen J; Jin YC; Guan Y; Sun Y; Xie QM
Toxicology; 2017 Aug; 389():31-41. PubMed ID: 28694203
[TBL] [Abstract][Full Text] [Related]
9. Effect of the p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat.
Birrell M; Hele D; McCluskie K; Webber S; Foster M; Belvisi MG
Eur Respir J; 2000 Nov; 16(5):947-50. PubMed ID: 11153597
[TBL] [Abstract][Full Text] [Related]
10. A p38 MAPK inhibitor, FR-167653, ameliorates murine bleomycin-induced pulmonary fibrosis.
Matsuoka H; Arai T; Mori M; Goya S; Kida H; Morishita H; Fujiwara H; Tachibana I; Osaki T; Hayashi S
Am J Physiol Lung Cell Mol Physiol; 2002 Jul; 283(1):L103-12. PubMed ID: 12060566
[TBL] [Abstract][Full Text] [Related]
11. The involvement of L-gamma-glutamyl-L-cysteinyl-glycine (glutathione/GSH) in the mechanism of redox signaling mediating MAPK(p38)-dependent regulation of pro-inflammatory cytokine production.
Haddad JJ
Biochem Pharmacol; 2002 Jan; 63(2):305-20. PubMed ID: 11841806
[TBL] [Abstract][Full Text] [Related]
12. p38 Mitogen-activated protein kinase up-regulates LPS-induced NF-kappaB activation in the development of lung injury and RAW 264.7 macrophages.
Kim HJ; Lee HS; Chong YH; Kang JL
Toxicology; 2006 Aug; 225(1):36-47. PubMed ID: 16793190
[TBL] [Abstract][Full Text] [Related]
13. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation.
Nick JA; Young SK; Brown KK; Avdi NJ; Arndt PG; Suratt BT; Janes MS; Henson PM; Worthen GS
J Immunol; 2000 Feb; 164(4):2151-9. PubMed ID: 10657669
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitor of p38 mitogen-activated protein kinase inhibits lipopolysaccharide-induced interleukin-8 expression in human pulmonary vascular endothelial cells.
Hashimoto S; Gon Y; Matsumoto K; Maruoka S; Takeshita I; Hayashi S; Asai Y; Jibiki I; Machino T; Horie T
J Pharmacol Exp Ther; 2000 May; 293(2):370-5. PubMed ID: 10773004
[TBL] [Abstract][Full Text] [Related]
15. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase.
Kumar S; Votta BJ; Rieman DJ; Badger AM; Gowen M; Lee JC
J Cell Physiol; 2001 Jun; 187(3):294-303. PubMed ID: 11319753
[TBL] [Abstract][Full Text] [Related]
16. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase.
Guo X; Gerl RE; Schrader JW
J Biol Chem; 2003 Jun; 278(25):22237-42. PubMed ID: 12637577
[TBL] [Abstract][Full Text] [Related]
17. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.
Ju H; Behm DJ; Nerurkar S; Eybye ME; Haimbach RE; Olzinski AR; Douglas SA; Willette RN
J Pharmacol Exp Ther; 2003 Dec; 307(3):932-8. PubMed ID: 14561851
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
Badger AM; Griswold DE; Kapadia R; Blake S; Swift BA; Hoffman SJ; Stroup GB; Webb E; Rieman DJ; Gowen M; Boehm JC; Adams JL; Lee JC
Arthritis Rheum; 2000 Jan; 43(1):175-83. PubMed ID: 10643714
[TBL] [Abstract][Full Text] [Related]
19. [Effects of phosphorylated mitogen-activated protein kinases on phosgene inhalation-induced lung injury in rats and its relationship with matrix metalloproteinase].
Shao YR; Shen J; Li W; Yuan Z; He DK
Zhonghua Shao Shang Za Zhi; 2013 Jun; 29(3):261-6. PubMed ID: 24059951
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation.
Brando Lima AC; Machado AL; Simon P; Cavalcante MM; Rezende DC; Sperandio da Silva GM; Nascimento PG; Quintas LE; Cunha FQ; Barreiro EJ; Lima LM; Koatz VL
Pharmacol Rep; 2011; 63(4):1029-39. PubMed ID: 22001991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
